Spain Liquid Biopsy Market By Offering (Testing Service, Kits, Platform, Other Consumables), By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others), By Application (Oncological, non-Oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region, Competition, Forecast and Opportunities, 2028
Spain Liquid Biopsy market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. The liquid Biopsy market in Spain has witnessed significant growth over the past few years, owing to the increasing investments in the liquid biopsy market in the country. In recent years, liquid biopsy has emerged as a promising diagnostic technique for the detection and monitoring of cancer and other diseases. As a result, the liquid biopsy market in Spain has been attracting increasing investments from both public and private sectors. These investments are helping to drive the growth of the liquid biopsy market in Spain, which is expected to continue to grow rapidly in the coming years.
One of the primary drivers of investment in the liquid biopsy market in Spain is the potential for liquid biopsy to transform cancer diagnosis and treatment. Traditional biopsy methods, which involve invasive procedures such as surgery or needle biopsy, can be painful, risky, and time-consuming. Liquid biopsy, on the other hand, is a non-invasive technique that can provide faster, more accurate, and less expensive diagnostic results. This potential for improved cancer care has attracted significant investment in liquid biopsy research and development in Spain.
Another driver of investment in the liquid biopsy market in Spain is the increasing prevalence of cancer in the country. According to the Spanish Society of Medical Oncology, cancer is the second leading cause of death in Spain, accounting for nearly 30% of all deaths. Also, according to the latest statistics, approximately 277,394 new cancer cases were diagnosed in Spain in 2020. This has created a significant demand for more effective and efficient cancer diagnosis and treatment, and liquid biopsy has the potential to meet this demand. Several factors contribute to the rising prevalence of cancer in Spain. One of the primary causes is the aging population. As the population of Spain ages, the risk of developing cancer increases significantly. According to the National Institute of Statistics, the percentage of people aged 65 and over in Spain increased from 19.2% in 2010 to 21.8% in 2020. This increase in the elderly population has led to a higher incidence of cancer.
Furthermore, the Spanish government has been actively supporting investment in the liquid biopsy market. In addition to government support, private sector investments in the liquid biopsy market in Spain are on the rise. Several startups and established companies in Spain are investing in liquid biopsy research and development, and some have already launched liquid biopsy products in the market. For example, Biocartis has launched a liquid biopsy test for colorectal cancer that is designed to be used with its diagnostic platform, Idylla.
Advancements in Liquid Biopsy Technology
One of the major advancements in liquid biopsy technology is the development of next-generation sequencing (NGS) technology. NGS technology allows for the analysis of multiple biomarkers simultaneously, providing more comprehensive information about the disease. This technology has significantly improved the accuracy and sensitivity of liquid biopsy tests, allowing for the detection of cancer at an early stage. NGS technology has enabled the detection of rare mutations that were previously undetectable, providing clinicians with more information about the disease and its progression.
Another significant advancement in liquid biopsy technology is the development of digital PCR (dPCR) technology. dPCR technology is a more precise and sensitive method of detecting and quantifying cancer biomarkers in body fluids. This technology has improved the accuracy of liquid biopsy tests, reduced false-negative results, and improved patient outcomes.
Liquid biopsy technology has been improved by the development of microfluidic devices. These devices allow for the isolation and analysis of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) from body fluids. This technology has significantly improved the sensitivity and specificity of liquid biopsy tests, enabling the detection of cancer at an early stage.
In addition, the development of machine learning and artificial intelligence (AI) algorithms has significantly improved the accuracy and reliability of liquid biopsy tests. These algorithms can analyze large datasets and identify patterns that may be indicative of cancer, providing clinicians with more accurate and reliable diagnostic information.
The development of liquid biopsy technology in Spain has been driven by government support for research and development activities, increasing investments in the market, and collaborations between academic institutions and industry partners. These efforts have led to the development of new liquid biopsy assays and technologies that are more accurate, reliable, and cost-effective.
Growing Adoption of Non-Invasive Diagnostic Techniques
Non-invasive diagnostic techniques have been gaining popularity in recent years, particularly in Spain, due to their convenience, safety, and accuracy. Non-invasive diagnostic techniques are medical tests that do not require the insertion of instruments or devices into the body, such as blood tests, ultrasound, and magnetic resonance imaging (MRI). In Spain, the adoption of non-invasive diagnostic techniques has been driven by several factors, including the increasing prevalence of chronic diseases, the aging population, and technological advancements.
One of the primary drivers of the growing adoption of non-invasive diagnostic techniques in Spain is the increasing prevalence of chronic diseases. Chronic diseases, such as cancer, cardiovascular disease, and diabetes, require ongoing monitoring and management. Non-invasive diagnostic techniques are well-suited for monitoring chronic diseases, as they can be performed more frequently and with less risk to the patient.
Moreover, the aging population in Spain has contributed to the growing adoption of non-invasive diagnostic techniques. As people age, they are more likely to develop chronic diseases and traditional diagnostic techniques may be more invasive and riskier for older adults. Non-invasive diagnostic techniques, such as ultrasound and MRI, are safer and more comfortable for older adults, making them a preferred option for diagnostic testing.
Technological advancements have played a significant role in the growing adoption of non-invasive diagnostic techniques in Spain. Advancements in medical imaging, such as ultrasound and MRI, have improved the accuracy and specificity of diagnostic tests, reducing the need for more invasive procedures, such as biopsies. In addition, the development of new blood tests, such as liquid biopsy, has enabled the detection and monitoring of diseases, such as cancer, without the need for invasive procedures.
The growing adoption of non-invasive diagnostic techniques in Spain has several benefits. Non-invasive techniques are less invasive and painful, reducing patient discomfort and improving patient satisfaction. Moreover, non-invasive techniques are generally safer than invasive procedures, reducing the risk of complications and infections. Hence, this technique can be performed more frequently, enabling earlier detection and more effective management of diseases.
Government Support for Liquid Biopsy Research in Spain
The Spanish government has been investing heavily in research and development activities related to liquid biopsy technology. The government has provided funding for academic institutions, research centres, and private companies to support the development of new liquid biopsy assays, devices, and technologies. This funding has enabled researchers to conduct more extensive studies and accelerate the development of new liquid biopsy tests.
In addition to funding, the Spanish government has been providing regulatory support for the development of liquid biopsy technology. The government has been working with regulatory agencies to streamline the approval process for new liquid biopsy tests, enabling researchers to bring new tests to market more quickly. This regulatory support has been critical in enabling researchers to commercialize new liquid biopsy tests, which can improve patient outcomes and reduce the burden of disease.
Furthermore, the Spanish government has been promoting collaboration between academic institutions and industry partners to advance liquid biopsy research. These collaborations have enabled researchers to share resources, knowledge, and expertise, which can accelerate the development of new liquid biopsy tests. The government has been providing incentives for private companies to invest in liquid biopsy research, such as tax breaks and grants.
For example, researchers in Spain have developed liquid biopsy tests that can detect cancer at an early stage and identify rare mutations that were previously undetectable.
The government's support for liquid biopsy research in Spain has several benefits. By supporting the development of new liquid biopsy tests, the government is enabling clinicians to diagnose diseases more accurately and monitor disease progression more effectively. This can improve patient outcomes and reduce the burden of disease. Moreover, the development of liquid biopsy technology can create new jobs and stimulate economic growth.
Market Segmentation
Spain liquid biopsy market can be segmented by offering, technology, workflow, sample, circulating biomarker, application, end user, and by region. Based on offering, the market can be segmented into testing service, kits, platform, and other consumables. Based on technology, the market can be divided into polymerase chain reactions, next generation sequencing, and others. Based on workflow, the market can be categorized into sample preparation, library preparation, sequencing, and data analysis & management. Based on sample, the market can be fragmented into blood, urine, saliva, and others. Based on circulating biomarker, the market can be segmented into circulating tumor cells (CTCs), cell free nucleic acids, exosomes & extracellular vesicles, and others. Based on application, the market can be split into oncological and non-oncological. The Oncological segment can be sub-segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, and others while the non-Oncological segment can be divided into treatment monitoring, prognosis & recurrence monitoring, treatment selection, and others. Based on end user, market can be categorized into clinical laboratories, academic & research institutes, and pharmaceutical & biotechnology companies.
Market Players
Thermo Fisher Scientific SL, Sysmex Espana S.L., OncoDNA SA, Atrys Health SA, Biocartis Group NV, are some of the leading players operating in the Spain Liquid Biopsy market.
Report Scope:
In this report, Spain Liquid Biopsy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Spain Liquid Biopsy Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
One of the primary drivers of investment in the liquid biopsy market in Spain is the potential for liquid biopsy to transform cancer diagnosis and treatment. Traditional biopsy methods, which involve invasive procedures such as surgery or needle biopsy, can be painful, risky, and time-consuming. Liquid biopsy, on the other hand, is a non-invasive technique that can provide faster, more accurate, and less expensive diagnostic results. This potential for improved cancer care has attracted significant investment in liquid biopsy research and development in Spain.
Another driver of investment in the liquid biopsy market in Spain is the increasing prevalence of cancer in the country. According to the Spanish Society of Medical Oncology, cancer is the second leading cause of death in Spain, accounting for nearly 30% of all deaths. Also, according to the latest statistics, approximately 277,394 new cancer cases were diagnosed in Spain in 2020. This has created a significant demand for more effective and efficient cancer diagnosis and treatment, and liquid biopsy has the potential to meet this demand. Several factors contribute to the rising prevalence of cancer in Spain. One of the primary causes is the aging population. As the population of Spain ages, the risk of developing cancer increases significantly. According to the National Institute of Statistics, the percentage of people aged 65 and over in Spain increased from 19.2% in 2010 to 21.8% in 2020. This increase in the elderly population has led to a higher incidence of cancer.
Furthermore, the Spanish government has been actively supporting investment in the liquid biopsy market. In addition to government support, private sector investments in the liquid biopsy market in Spain are on the rise. Several startups and established companies in Spain are investing in liquid biopsy research and development, and some have already launched liquid biopsy products in the market. For example, Biocartis has launched a liquid biopsy test for colorectal cancer that is designed to be used with its diagnostic platform, Idylla.
Advancements in Liquid Biopsy Technology
One of the major advancements in liquid biopsy technology is the development of next-generation sequencing (NGS) technology. NGS technology allows for the analysis of multiple biomarkers simultaneously, providing more comprehensive information about the disease. This technology has significantly improved the accuracy and sensitivity of liquid biopsy tests, allowing for the detection of cancer at an early stage. NGS technology has enabled the detection of rare mutations that were previously undetectable, providing clinicians with more information about the disease and its progression.
Another significant advancement in liquid biopsy technology is the development of digital PCR (dPCR) technology. dPCR technology is a more precise and sensitive method of detecting and quantifying cancer biomarkers in body fluids. This technology has improved the accuracy of liquid biopsy tests, reduced false-negative results, and improved patient outcomes.
Liquid biopsy technology has been improved by the development of microfluidic devices. These devices allow for the isolation and analysis of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) from body fluids. This technology has significantly improved the sensitivity and specificity of liquid biopsy tests, enabling the detection of cancer at an early stage.
In addition, the development of machine learning and artificial intelligence (AI) algorithms has significantly improved the accuracy and reliability of liquid biopsy tests. These algorithms can analyze large datasets and identify patterns that may be indicative of cancer, providing clinicians with more accurate and reliable diagnostic information.
The development of liquid biopsy technology in Spain has been driven by government support for research and development activities, increasing investments in the market, and collaborations between academic institutions and industry partners. These efforts have led to the development of new liquid biopsy assays and technologies that are more accurate, reliable, and cost-effective.
Growing Adoption of Non-Invasive Diagnostic Techniques
Non-invasive diagnostic techniques have been gaining popularity in recent years, particularly in Spain, due to their convenience, safety, and accuracy. Non-invasive diagnostic techniques are medical tests that do not require the insertion of instruments or devices into the body, such as blood tests, ultrasound, and magnetic resonance imaging (MRI). In Spain, the adoption of non-invasive diagnostic techniques has been driven by several factors, including the increasing prevalence of chronic diseases, the aging population, and technological advancements.
One of the primary drivers of the growing adoption of non-invasive diagnostic techniques in Spain is the increasing prevalence of chronic diseases. Chronic diseases, such as cancer, cardiovascular disease, and diabetes, require ongoing monitoring and management. Non-invasive diagnostic techniques are well-suited for monitoring chronic diseases, as they can be performed more frequently and with less risk to the patient.
Moreover, the aging population in Spain has contributed to the growing adoption of non-invasive diagnostic techniques. As people age, they are more likely to develop chronic diseases and traditional diagnostic techniques may be more invasive and riskier for older adults. Non-invasive diagnostic techniques, such as ultrasound and MRI, are safer and more comfortable for older adults, making them a preferred option for diagnostic testing.
Technological advancements have played a significant role in the growing adoption of non-invasive diagnostic techniques in Spain. Advancements in medical imaging, such as ultrasound and MRI, have improved the accuracy and specificity of diagnostic tests, reducing the need for more invasive procedures, such as biopsies. In addition, the development of new blood tests, such as liquid biopsy, has enabled the detection and monitoring of diseases, such as cancer, without the need for invasive procedures.
The growing adoption of non-invasive diagnostic techniques in Spain has several benefits. Non-invasive techniques are less invasive and painful, reducing patient discomfort and improving patient satisfaction. Moreover, non-invasive techniques are generally safer than invasive procedures, reducing the risk of complications and infections. Hence, this technique can be performed more frequently, enabling earlier detection and more effective management of diseases.
Government Support for Liquid Biopsy Research in Spain
The Spanish government has been investing heavily in research and development activities related to liquid biopsy technology. The government has provided funding for academic institutions, research centres, and private companies to support the development of new liquid biopsy assays, devices, and technologies. This funding has enabled researchers to conduct more extensive studies and accelerate the development of new liquid biopsy tests.
In addition to funding, the Spanish government has been providing regulatory support for the development of liquid biopsy technology. The government has been working with regulatory agencies to streamline the approval process for new liquid biopsy tests, enabling researchers to bring new tests to market more quickly. This regulatory support has been critical in enabling researchers to commercialize new liquid biopsy tests, which can improve patient outcomes and reduce the burden of disease.
Furthermore, the Spanish government has been promoting collaboration between academic institutions and industry partners to advance liquid biopsy research. These collaborations have enabled researchers to share resources, knowledge, and expertise, which can accelerate the development of new liquid biopsy tests. The government has been providing incentives for private companies to invest in liquid biopsy research, such as tax breaks and grants.
For example, researchers in Spain have developed liquid biopsy tests that can detect cancer at an early stage and identify rare mutations that were previously undetectable.
The government's support for liquid biopsy research in Spain has several benefits. By supporting the development of new liquid biopsy tests, the government is enabling clinicians to diagnose diseases more accurately and monitor disease progression more effectively. This can improve patient outcomes and reduce the burden of disease. Moreover, the development of liquid biopsy technology can create new jobs and stimulate economic growth.
Market Segmentation
Spain liquid biopsy market can be segmented by offering, technology, workflow, sample, circulating biomarker, application, end user, and by region. Based on offering, the market can be segmented into testing service, kits, platform, and other consumables. Based on technology, the market can be divided into polymerase chain reactions, next generation sequencing, and others. Based on workflow, the market can be categorized into sample preparation, library preparation, sequencing, and data analysis & management. Based on sample, the market can be fragmented into blood, urine, saliva, and others. Based on circulating biomarker, the market can be segmented into circulating tumor cells (CTCs), cell free nucleic acids, exosomes & extracellular vesicles, and others. Based on application, the market can be split into oncological and non-oncological. The Oncological segment can be sub-segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, and others while the non-Oncological segment can be divided into treatment monitoring, prognosis & recurrence monitoring, treatment selection, and others. Based on end user, market can be categorized into clinical laboratories, academic & research institutes, and pharmaceutical & biotechnology companies.
Market Players
Thermo Fisher Scientific SL, Sysmex Espana S.L., OncoDNA SA, Atrys Health SA, Biocartis Group NV, are some of the leading players operating in the Spain Liquid Biopsy market.
Report Scope:
In this report, Spain Liquid Biopsy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Spain Liquid Biopsy Market, By Offering:
- Testing Service
- Kits
- Platform
- Other Consumables
- Spain Liquid Biopsy Market, By Technology:
- Polymerase Chain Reactions
- Next Generation Sequencing
- Others
- Spain Liquid Biopsy Market, By Workflow:
- Sample Preparation
- Library Preparation
- Sequencing
- Data Analysis & Management
- Spain Liquid Biopsy Market, By Sample:
- Blood
- Urine
- Saliva
- Others
- Spain Liquid Biopsy Market, By Circulating Biomarker:
- Circulating Tumor Cells (CTCs)
- Cell Free Nucleic Acids
- Exosomes & Extracellular Vesicles
- Others
- Spain Liquid Biopsy Market, By Application:
- Oncological
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Others
- non-Oncological
- Treatment Monitoring
- Prognosis & Recurrence Monitoring
- Treatment Selection
- Others
- Spain Liquid Biopsy Market, By End User:
- Clinical Laboratories
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Spain Liquid Biopsy Market, By Region:
- Central Region North Spain
- Aragon & Catalonia
- Andalusia, Murcia & Valencia
- Madrid, Extremadura & Castilla
Company Profiles: Detailed analysis of the major companies present in the Spain Liquid Biopsy Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. PATENTS ANALYSIS
7. SPAIN LIQUID BIOPSY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
7.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
7.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
7.2.4. By Sample (Blood, Urine, Saliva, Others)
7.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
7.2.6. By Application (Oncological v/s non-Oncological)
7.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
7.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
7.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
7.2.8. By Region (Central Region North Spain; Aragon & Catalonia; Andalusia, Murcia & Valencia; Madrid, Extremadura & Castilla)
7.2.9. By Company (2022)
7.3. Market Map
7.3.1. By Offering
7.3.2. By Technology
7.3.3. By Workflow
7.3.4. By Sample
7.3.5. By Circulating Biomarker
7.3.6. By Application
7.3.7. By End User
7.3.8. By Region
8. CENTRAL REGION NORTH SPAIN LIQUID BIOPSY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
8.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
8.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
8.2.4. By Sample (Blood, Urine, Saliva, Others)
8.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
8.2.6. By Application (Oncological v/s non-Oncological)
8.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
9. ARAGON & CATALONIA LIQUID BIOPSY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
9.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
9.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
9.2.4. By Sample (Blood, Urine, Saliva, Others)
9.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
9.2.6. By Application (Oncological v/s non-Oncological)
9.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
10. ANDALUSIA, MURCIA & VALENCIA LIQUID BIOPSY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
10.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
10.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
10.2.4. By Sample (Blood, Urine, Saliva, Others)
10.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
10.2.6. By Application (Oncological v/s non-Oncological)
10.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
11. MADRID, EXTREMADURA & CASTILLA LIQUID BIOPSY MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
11.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
11.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
11.2.4. By Sample (Blood, Urine, Saliva, Others)
11.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
11.2.6. By Application (Oncological v/s non-Oncological)
11.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches
14. POLICY & REGULATORY LANDSCAPE
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. SPAIN ECONOMIC PROFILE
17. COMPETITIVE LANDSCAPE
17.1. Business Overview
17.2. Product Offerings
17.3. Recent Developments
17.4. Financials (As Reported)
17.5. Key Personnel
17.6. SWOT Analysis
17.6.1. Thermo Fisher Scientific SL
17.6.2. Sysmex Espana S.L.
17.6.3. OncoDNA SA
17.6.4. Atrys Health SA
17.6.5. Biocartis Group NV
18. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. PATENTS ANALYSIS
7. SPAIN LIQUID BIOPSY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
7.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
7.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
7.2.4. By Sample (Blood, Urine, Saliva, Others)
7.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
7.2.6. By Application (Oncological v/s non-Oncological)
7.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
7.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
7.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
7.2.8. By Region (Central Region North Spain; Aragon & Catalonia; Andalusia, Murcia & Valencia; Madrid, Extremadura & Castilla)
7.2.9. By Company (2022)
7.3. Market Map
7.3.1. By Offering
7.3.2. By Technology
7.3.3. By Workflow
7.3.4. By Sample
7.3.5. By Circulating Biomarker
7.3.6. By Application
7.3.7. By End User
7.3.8. By Region
8. CENTRAL REGION NORTH SPAIN LIQUID BIOPSY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
8.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
8.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
8.2.4. By Sample (Blood, Urine, Saliva, Others)
8.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
8.2.6. By Application (Oncological v/s non-Oncological)
8.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
9. ARAGON & CATALONIA LIQUID BIOPSY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
9.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
9.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
9.2.4. By Sample (Blood, Urine, Saliva, Others)
9.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
9.2.6. By Application (Oncological v/s non-Oncological)
9.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
10. ANDALUSIA, MURCIA & VALENCIA LIQUID BIOPSY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
10.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
10.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
10.2.4. By Sample (Blood, Urine, Saliva, Others)
10.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
10.2.6. By Application (Oncological v/s non-Oncological)
10.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
11. MADRID, EXTREMADURA & CASTILLA LIQUID BIOPSY MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
11.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
11.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
11.2.4. By Sample (Blood, Urine, Saliva, Others)
11.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
11.2.6. By Application (Oncological v/s non-Oncological)
11.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches
14. POLICY & REGULATORY LANDSCAPE
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. SPAIN ECONOMIC PROFILE
17. COMPETITIVE LANDSCAPE
17.1. Business Overview
17.2. Product Offerings
17.3. Recent Developments
17.4. Financials (As Reported)
17.5. Key Personnel
17.6. SWOT Analysis
17.6.1. Thermo Fisher Scientific SL
17.6.2. Sysmex Espana S.L.
17.6.3. OncoDNA SA
17.6.4. Atrys Health SA
17.6.5. Biocartis Group NV
18. STRATEGIC RECOMMENDATIONS
